Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049699 · ClinicalTrials.gov registry record · Phase 1
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
A Phase 1 study of Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific, sponsored by Vion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Study locations
NCT00049699: Completed Phase 1 study of Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific, sponsored by Vion Pharmaceuticals.
NCT00049699 is a Phase 1 study of Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by Vion Pharmaceuticals. The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00049699, a Phase 1 study of Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by Vion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have advanced or metastatic cancer.
Conditions Studied
Interventions
- DRUG laromustine
Study Locations (3)
Connecticut
- Yale Comprehensive Cancer Center - New Haven
- Veterans Affairs Medical Center - West Haven - West Haven
Ohio
- Ireland Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-10 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
What the finished NCT00049699 record still lists
NCT00049699 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which laromustine is the first listed.
NCT00049699 reports a single indexed study location in Connecticut, Ohio.
Frequently Asked Questions
What is clinical trial NCT00049699 about?
NCT00049699 is a clinical study titled "VNP40101M in Treating Patients With Advanced or Metastatic Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have advanced or metastatic cancer.
What is the current status of trial NCT00049699?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-10. Estimated completion is 2008-01.
What conditions does trial NCT00049699 study?
This clinical trial studies the following conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Small Intestine Cancer.
What interventions are being tested in trial NCT00049699?
The interventions under investigation include: laromustine (DRUG).
Who is sponsoring clinical trial NCT00049699?
This trial is sponsored by Vion Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00049699 being conducted?
This trial has 3 study locations across Connecticut, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia